Alnylam Pharmaceuticals Files Proxy Statement Amendment
Ticker: ALNY · Form: DEFA14A · Filed: Apr 4, 2025 · CIK: 1178670
| Field | Detail |
|---|---|
| Company | Alnylam Pharmaceuticals, Inc. (ALNY) |
| Form Type | DEFA14A |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, amendment
Related Tickers: ALNY
TL;DR
ALNY filed proxy amendment, annual meeting prep underway.
AI Summary
Alnylam Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement on April 4, 2025. This filing is related to the solicitation of proxies for its upcoming annual meeting. The company is based in Cambridge, MA, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates that Alnylam Pharmaceuticals is proceeding with its corporate governance processes, including the solicitation of shareholder votes for its annual meeting.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to corporate governance and does not contain new material financial information or strategic changes.
Key Players & Entities
- ALNYLAM PHARMACEUTICALS, INC. (company) — Registrant
- 0001178670-25-000044 (filing_id) — Accession Number
- 20250404 (date) — Filing Date
- 675 WEST KENDALL STREET (address) — Business Address
- CAMBRIDGE (city) — Business Address City
- MA (state) — Business Address State
- 02142 (zip_code) — Business Address Zip
FAQ
What type of filing is this?
This is a Definitive Additional Materials filing, specifically Amendment No. 1 to a Schedule 14A Proxy Statement.
Who is the filing company?
The filing company is Alnylam Pharmaceuticals, Inc.
When was this amendment filed?
This amendment was filed on April 4, 2025.
What is the company's primary business sector?
The company is in the Pharmaceutical Preparations [2834] industry.
Where is the company headquartered?
The company's business address is 675 West Kendall Street, Cambridge, MA 02142.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 4, 2025 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).